Janux Therapeutics (JANX) to Release Earnings on Thursday

Janux Therapeutics (NASDAQ:JANX) will likely be posting its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Janux Therapeutics to announce earnings of ($0.26) per share and revenue of $19.0750 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Friday, August 14, 2026 at 4:00 PM ET.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.13. The business had revenue of $3.73 million during the quarter, compared to the consensus estimate of $4.36 million. On average, analysts expect Janux Therapeutics to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Janux Therapeutics Stock Performance

JANX stock traded up $0.36 during midday trading on Tuesday, reaching $15.68. 66,988 shares of the company’s stock traded hands, compared to its average volume of 1,156,426. The company has a 50-day moving average price of $14.93 and a two-hundred day moving average price of $14.39. Janux Therapeutics has a 52 week low of $12.12 and a 52 week high of $35.34. The firm has a market capitalization of $956.41 million, a PE ratio of -8.49 and a beta of 2.50.

Insider Buying and Selling at Janux Therapeutics

In other Janux Therapeutics news, VP Maria Dobek sold 2,038 shares of the company’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $14.17, for a total value of $28,878.46. Following the transaction, the vice president directly owned 32,270 shares in the company, valued at $457,265.90. This represents a 5.94% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Janeen Noel Doyle sold 4,059 shares of the firm’s stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $14.03, for a total value of $56,947.77. Following the completion of the sale, the insider directly owned 75,941 shares in the company, valued at approximately $1,065,452.23. The trade was a 5.07% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 7.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of JANX. Osaic Holdings Inc. lifted its position in Janux Therapeutics by 704.6% during the second quarter. Osaic Holdings Inc. now owns 3,468 shares of the company’s stock valued at $80,000 after purchasing an additional 3,037 shares during the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of Janux Therapeutics by 175.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company’s stock worth $91,000 after buying an additional 2,502 shares during the last quarter. BNP Paribas Financial Markets raised its position in shares of Janux Therapeutics by 185.1% during the 2nd quarter. BNP Paribas Financial Markets now owns 7,673 shares of the company’s stock valued at $177,000 after buying an additional 4,982 shares in the last quarter. AQR Capital Management LLC raised its position in shares of Janux Therapeutics by 71.7% during the 1st quarter. AQR Capital Management LLC now owns 9,717 shares of the company’s stock valued at $262,000 after buying an additional 4,059 shares in the last quarter. Finally, Jain Global LLC bought a new stake in shares of Janux Therapeutics during the 3rd quarter worth $241,000. 75.39% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on JANX. Wedbush reduced their price target on Janux Therapeutics from $45.00 to $36.00 and set an “outperform” rating for the company in a research report on Friday, May 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Janux Therapeutics in a research note on Monday, July 20th. JonesTrading reduced their target price on Janux Therapeutics from $50.00 to $28.00 and set a “buy” rating for the company in a report on Tuesday, April 28th. Piper Sandler decreased their price target on Janux Therapeutics from $30.00 to $26.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Finally, Evercore set a $22.00 price target on Janux Therapeutics in a research report on Monday, May 11th. Nine research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $38.08.

About Janux Therapeutics

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.